NASD · Healthcare · Biotechnology · Australia
Clinuvel Pharmaceuticals Ltd ADR is a micro cap company (market value under $300 million) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Clinuvel Pharmaceuticals Ltd ADR stock.
Undervalued: intrinsic value $11.79 per share, market price $5.07, margin of safety 57.0% (as of 2026-10-30).
Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $11.79; the price of $5.07 is 57% below that value, and 74% of that value comes from beyond year five.
5 more in this industry show a wider margin of safety.
CUVL is undervalued (as of the 2026-10-30 close). Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $11.79; the price of $5.07 is 57% below that value, and 74% of that value comes from beyond year five.
$11.79 per share (as of the 2026-10-30 close), against a market price of $5.07. That is a margin of safety of 57.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.